We are proven
We are a biotechnology company developing novel small molecule multi-pathway modulators for the treatment of cancer, fibrosis, and inflammatory diseases. We have amassed a significant wealth of expertise in our therapeutic areas of interest, with decades of drug development experience.
Recent News and Publications
NovoMedix Presents New Preclinical Data on NMX2 at the 2022 American Heart Association (AHA) Scientific Sessions Meeting
SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- NovoMedix, LLC ("NovoMedix"), a biotechnology company developing novel, multi-pathway modulators for ...
AHA 2022 Meeting
The premier global event focusing on improving health by championing scientific discovery and practice-changing educational ...
Our therapies modulate key pathways of cancer, fibrosis and lung disease
Our novel therapeutic candidates target well-known hallmarks of disease that drive cancer, fibrotic and cardio-oncology indications. We have built a broad pipeline stemming from our proprietary technology platform, which consists of a library of oral small molecule IL-11 inhibitors with compelling data in animal models of cancer and fibrosis coupled with remarkable safety profiles.
NMX1, our lead oral small molecule candidate, inhibits mTOR signaling and secretion of IL-11 to treat the tumor while activating AMPK to protect the heart in TNBC. The company is also advancing several candidates designed to treat fibrotic diseases, liquid tumors, and atopic dermatitis.
“Working at NovoMedix has provided me so many opportunities to grow and learn in the exicting field of cancer and fibrosis drug development. I look forward to helping NovoMedix transform patients’ lives with our novel approach.”
Igor Belka, Senior Research Associate